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Introduction
Primary liver cancer (PLC), one of the most common solid 
tumor types, is a leading cause for cancer- related death 
around the world [1, 2]. Histologically, PLC can be roughly 
divided into three main subtypes: hepatocellular carcinoma 
(HCC), intrahepatic cholangiocarcinoma (ICC) and mixed 
hepatocellular–cholangiocellular carcinoma according to dif-
ferent cell origin [3]. HCC is the major histopathologic 
subtype of PLC, accounting for more than 80% of the 
total intrahepatic primary malignancies [4, 5]. Originating 
from the epithelial cells of the intrahepatic bile ducts, ICC 
ranks the second most prevalent primary hepatic malignancy, 
accounting for 10%~15% of PLC [6]. Although ICC is 
less common than HCC, the incidence of ICC has been 
increasing drastically without clear and specific etiology in 
the United States during the past two decades, ranging 
from 0.72 to 0.88 per 100,000 [7–9]. In spite of recent 
advances in basic research and clinical trials, ICC report-
edly bears a 5- year survival of only about 30% [10].
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Abstract
Intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) 
are the most prevalent histologic types of primary liver cancer (PLC). Although 
ICC and HCC share similar risk factors and clinical manifestations, ICC usually 
bears poorer prognosis than HCC. Confidently discriminating ICC and HCC 
before surgery is beneficial to both treatment and prognosis. Given the lack of 
effective differential diagnosis biomarkers and methods, construction of models 
based on available clinicopathological characteristics is in need. Nomograms 
present a simple and efficient way to make a discrimination. A total of 2894 
patients who underwent surgery for PLC were collected. Of these, 1614 patients 
formed the training cohort for nomogram construction, and thereafter, 1280 
patients formed the validation cohort to confirm the model’s performance. His-
topathologically confirmed ICC was diagnosed in 401 (24.8%) and 296 (23.1%) 
patients in these two cohorts, respectively. A nomogram  integrating six easily 
obtained variables (Gender, Hepatitis B surface antigen, Aspartate aminotrans-
ferase, Alpha- fetoprotein, Carcinoembryonic antigen, Carbohydrate antigen 19- 9) 
is proposed in accordance with Akaike’s Information Criterion (AIC). A score 
of 15 was determined as the cut- off value, and the corresponding discrimination 
efficacy was sufficient. Additionally, patients who scored higher than 15 suffered 
poorer prognosis than those with lower scores, regardless of the subtype of 
PLC. A nomogram for clinical discrimination of ICC and HCC has been es-
tablished, where a higher score indicates ICC and poor prognosis. Further ap-
plication of this nomogram in multicenter investigations may confirm the prac-
ticality of this tool for future clinical use. 
Cancer Medicine
Open Access
647© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
A Nomogram for Discriminating ICC and HCCM. Wang et al.
As a malignant neoplasm, ICC and HCC frequently 
share common risk factors and clinical manifestations. 
However, as reported, attributing to different molecular 
characteristics and carcinogenic mechanisms, survival and 
prognosis of patients with ICC are more dismal than those 
with HCC [11]. Although surgical resection is the first- line 
treatment for HCC patients [12, 13], the best treatment 
option for ICC patients remains less defined, where com-
mon procedures differ between curative resection, chemo-
therapy, stereotactic radiotherapy, intra- arterial therapy or 
multimodality treatment [14–16]. As treatment modalities 
and clinical outcomes of ICC and HCC differ significantly, 
confidently discriminating between these two subtypes of 
PLC before making a medical decision has attracted more 
emphasis [17]. Although magnetic resonance imaging (MRI) 
is a common emerging diagnostic procedure to discriminate 
the two subtypes, it still can be unfeasible in situations 
where patients cannot safely use an MRI or where the 
device is not easily accessible, and other methods such as 
ultrasound can still provide indistinguishable results [18, 
19]. As a result, alpha- fetoprotein (AFP) and carbohydrate 
antigen 19- 9 (CA19- 9) are regarded as the optimal serum 
tumor markers for HCC and ICC, respectively. However, 
these two can also be unreliable, as the diagnostic sensitiv-
ity and specificity of these biomarkers are unsatisfactory, 
meaning better- performing biomarkers are still needed [20, 
21]. Although many studies have been conducted to inves-
tigate the unique characteristics of ICC and find new dif-
ferential diagnosis biomarkers or tools for distinguishing 
ICC from HCC, progress in clinical applications has still 
been limited [22, 23].
Given the lack of highly sensitive and specific predictive 
biomarkers and methods for ICC diagnosis, establishment 
of a predictive model that incorporates relevant factors 
can be another way to solve this issue. Nomograms, simple 
graphical systems, have been emerging in recent years 
and may be more accurate in preoperative diagnosis or 
prognostic evaluation than traditional methods for a variety 
of malignant neoplasms, including liver cancer [24, 25], 
pancreatic adenocarcinoma [26] and perihilar cholangio-
carcinoma [27]. In order to distinguish ICC from HCC 
before surgery without pathological validation, in this 
study, we aimed to establish and validate a differential 
diagnostic nomogram model for ICC and HCC based on 
the big data of the demographic characteristics and the 
results of routine laboratory tests.
Materials and Methods
Patient selection and study design
From January 2007 to January 2010, a total of 1614  eligible 
patients who received curative surgery for PLC at Eastern 
Hepatobiliary Surgery Hospital (EHBH, Shanghai, China) 
were recruited as the training cohort for the development 
of the nomogram model. In addition, 1280 patients with 
PLC at EHBH from January 2010 to January 2012 were 
enrolled in the validation cohort.
The inclusion criteria included the following: (1) his-
tologic diagnosis was validated by post- operative patho-
logical examination, and (2) patient age fell between 40 
and 60. Cause for exclusion included the following: (1) 
incomplete clinical information; (2) mixed hepatocellu-
lar–cholangiocellular carcinoma or other types of liver 
tumor were diagnosed; (3) patient history included other 
cancers; (4) preoperative treatment was administered.
All procedures involving human participants have been 
approved by the EHBH research ethics committee and 
have been performed in accordance with the 1964 Helsinki 
declaration and its later amendments or comparable ethi-
cal standards. Informed consent was obtained from all 
individual participants in advance.
Follow- up study
Apart from the two aforementioned retrospective study 
groups (training cohort and validation cohort), a small- 
scale follow- up study was conducted to compare the 
prognosis of the patients with ICC or HCC who received 
liver resection at our EHBH from January 2012 to January 
2013. The enrolled patients were consecutively visited every 
2 months for 2 years after the surgery and then every 
3–6 months thereafter. Follow- up discontinued at the time 
of cancer recurrence or cancer- induced death. Overall 
survival (OS) was defined as the interval between opera-
tion and death or the time of latest visit. Recurrence- free 
survival (RFS) was measured from hepatectomy to the 
date when recurrence/metastasis was detected.
Laboratory measurement
Peripheral blood samples were collected after 12 h of 
fasting before surgery and were measured at the Department 
of Laboratory Medicine of EHBH. Patients underwent 
preoperative laboratory tests that included the following: 
aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), γ- glutamyl transferase (GGT), alkaline phosphatase 
(ALP), adenosine deaminase (ADA), total bile acid (TBA), 
total bilirubin (TBIL), direct bilirubin (DBIL), total protein 
(TP), prealbumin (PA), albumin (ALB), prothrombin time 
(PT), activated partial thromboplastin time (APTT), hepa-
titis B surface antigen (HBsAg), AFP, CA19- 9, carcinoem-
bryonic antigen (CEA), complete blood count, etc. All 
results of these clinical laboratory tests were gathered as 
complete and comprehensive as possible.
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Statistical analysis
Baseline demographic information, results from the clinical 
laboratory tests and pathological studies, was collected and 
summarized in Table 1. Continuous variables are expressed 
as mean (SD) and compared using an unpaired student’s 
t- test or Mann–Whitney test. Categorical variables were com-
pared using the Pearson’s χ2 test or Fisher exact test. Survival 
curves were estimated using the Kaplan–Meier method, and 
differences were compared using the log- rank test. Univariate 
logistic regression analysis was adopted to assess the differ-
ences in each potential factor in the training dataset for 
investigating independent risk factors for ICC. All variables 
associated with ICC at a significant level were the underlying 
candidates for stepwise multivariate analysis.
For nomogram construction, the most favorable model 
was screened and finally selected by multivariate logistic 
regression analysis using the Akaike’s Information Criterion 
(AIC) as a stopping rule [28]. The nomogram is based 
on transforming each variable’s coefficient in the multi-
variate logistic regression into a 0- to 10- point scale, pro-
portionally. The effect of the variable with the highest β 
(absolute value) coefficient is assigned 10 points. Total 
scores, the sum of each included variable’s point, are then 
converted to the risk probabilities of ICC presence. The 
concordance index (C- index) was used to provide an esti-
mate of the discrimination performance of the nomogram. 
A bootstrap method with 1000 resamples was implemented 
for model calibration to quantify the overfitting bias.
The diagnostic power of our nomogram model was 
assessed by a receiver operating characteristic (ROC) curve 
and the area under ROC curve (AUC), and the optimum 
cut- off value for clinical use was determined by maximiz-
ing the Youden index (sensitivity + specificity − 1).
All the statistical tests were two- tailed and P < 0.05 
was considered to indicate statistical significance. All analy-
ses were performed by SPSS statistical software (SPSS Inc., 
Chicago, IL, version 22.0 for Windows) and the “rms” 
package of R, version 3.2.3.
Results
Demographic information and 
clinicopathological characteristics
In total, 2894 patients who received hepatic resection for 
PLC and met the study criteria were enrolled in this 
retrospective investigation. One thousand six hundred and 
fourteen and 1280 patients were included in the training 
cohort and validation cohort, respectively. As shown in 
Table 1, the clinicopathological and laboratory character-
istics were similar between these two datasets. 
Histopathologically identified ICC was found in 401 
(24.8%) and 296 (23.1%) patients in the training and 
validation cohort, respectively.
Poorer prognosis of ICC patients
A follow- up survey was implemented on 100 ICC and 
330 HCC patients. The 1- and 3- year OS rates of ICC 
were 59.5% and 37%, and those of HCC were 89.4% 
and 76.5%, respectively. The post- operative 1- and 3- year 
RFS of ICC were 39.3% and 31.5% and those of HCC 
were 72.3% and 67.3%, respectively. The log- rank test 
showed that there were significant differences between 
ICC and HCC in the OS and RFS (P < 0.01, Fig. 1A 
and B), indicating that ICC patients suffer a poorer prog-
nosis than HCC patients.
Establishment and validation of an ICC–HCC 
differential diagnosis nomogram model
The results of univariate logistic analysis are summarized 
in Table 2, and 18 candidate variables present significant 
differences between ICC and HCC in the training cohort. 
As listed in Table 3, Gender, HBsAg, AFP, CEA, CA19- 9, 
AST, ADA, TP, TBA, ALP and PT were independently 
associated with ICC based on the multivariate analysis.
In accordance with AIC, the top six variables (Gender, 
HBsAg, CA19- 9, AFP, CEA and AST) were finally screened 
and integrated, which were mainly sorted based on β 
coefficient (absolute value) in the training cohort. A 
nomogram for discriminating ICC and HCC is demon-
strated in Figure 2A. The model displays a C- index of 
0.86 (95% CI: 0.84–0.88), presenting a sufficient accuracy 
in differentiating ICC from HCC. The calibration plots 
revealed sufficient agreement between the nomogram and 
histopathologic examination results (Fig. 2B).
In the validation cohort, the C- index was 0.88 (95% 
CI: 0.85–0.89), which also demonstrating that this nomo-
gram model was sufficient in distinguishing ICC from 
HCC. There was also a sufficient calibration curve for 
the ICC presence probability estimation (Fig. 2C).
A nomogram score of 15 was determined as the optimal 
cut- off value when the Youden index reached the maxi-
mum. As demonstrated in Table 4, the sensitivity, speci-
ficity, positive predictive value, and negative predictive 
value when using this model for differential diagnosis of 
ICC and HCC in the training cohort were 76.8%, 82.9%, 
59.7% and 91.5%, and those of the validation cohort 
were 76.6%, 80.7%, 54.4% and 92%, respectively. The 
summary statistics of each candidate risk factor is listed 
in Table S1, which illustrates that no one variable alone 
can give satisfactory discrimination. Intriguingly, we also 
found that patients of either subtype who received a high- 
risk score (>15, n = 122) based on this nomogram model 
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suffered a more dismal prognosis than those who received 
a low- risk score (≤15, n = 308) (Fig. 1C and D).
Discussion
Intrahepatic cholangiocarcinoma is a relatively rare cancer 
but with increasing incidence and mortality [29, 30]. It 
shares several etiological risk factors and clinical presenta-
tions to HCC, but therapeutic strategies and prognoses 
differ significantly between these two major PLC subtypes, 
which make correct differentiation of ICC from HCC a 
major issue in clinical practice [19].
Intensive efforts have been devoted to assist clinicians 
in unveiling the differences between ICC and HCC. 
However, accurate discrimination of ICC from HCC 
before surgery or biopsy remains difficult when single 
or multiple masses are detected in the liver, or access 
to imaging methods remains limited. Several clinico-
pathological differences between patients with ICC and 
HCC have been elucidated and potential factors influ-
encing survival have been identified, but a differential 
diagnosis model for ICC and HCC has still failed to be 
investigated for clinical use [31]. New research focused 
on discriminating the two subtypes have redirected focus 
to their fundamental differences to assist in clinical diag-
nostics. In genetics, differentially expressed gene profiles 
Table 1. Demographic information and clinicopathological characteris-
tics of training and validation cohorts.
Variables
Cohort, n (%)
Training (n = 1614) Validation (n = 1280)
Age, mean (SD), 
years
50.71 (5.79) 50.41 (5.98)
Gender (Male, %) 1341 (83.1) 1064 (83.1)
Liver Cirrhosis
Positive 772 (47.8) 652 (50.9)
Negative 842 (52.2) 628 (49.1)
Tumor size
>3 cm 1282 (77.5) 1044 (81.6)
≤3 cm 332 (22.5) 236 (18.4)
Tumor Capsule
Incomplete 1145 (70.9) 766 (59.8)
Complete 469 (29.1) 514 (40.2)
HBsAg
Positive 1308 (81.0) 1029 (80.4)
Negative 306 (19.0) 251 (19.6)
AFP
<20 ng/mL 801 (49.6) 626 (48.9)
20–400 ng/mL 377 (23.4) 285 (22.3)
>400 ng/mL 436 (27.0) 369 (28.8)
CA19- 9
≥39 U/mL 434 (26.9) 361 (28.2)
<39 U/mL 1180 (73.1) 919 (71.8)
CEA
≥10 μg/L 69 (4.3) 52 (4.1)
<10 μg/L 1545 (95.7) 1228 (95.9)
ALT
≥45 U/L 501 (31.0) 437 (34.1)
<45 U/L 1113 (69.0) 843 (65.9)
AST
≥40 U/L 512 (31.7) 471 (36.8)
<40 U/L 1102 (68.3) 809 (63.2)
GGT
≥60 U/L 865 (53.6) 736 (57.5)
<60 U/L 749 (46.4) 544 (42.5)
ALP
≥125 U/L 320 (19.8) 284 (22.4)
<125 U/L 1294 (80.2) 996 (77.8)
ADA
≥7 U/L 869 (53.8) 942 (73.6)
<7 U/L 745 (46.2) 338 (26.4)
TP
≥65 g/L 1331 (82.5) 1141 (89.1)
<65 g/L 283 (17.5) 139 (10.9)
ALB
≥40 g/L 1124 (69.6) 886 (69.2)
<40 g/L 490 (30.4) 394 (30.8)
PA
≥170 mg/L 1232 (76.3) 989 (77.3)
<170 mg/L 382 (23.7) 291 (22.7)
TBIL
>20.52 μmol/L 214 (13.3) 168 (13.1)
≤20.52 μmol/L 1400 (86.7) 1112 (86.9)
DBIL
>6.84 μmol/L 378 (23.4) 270 (21.1)




Training (n = 1614) Validation (n = 1280)
TBA
≥12 μmol/L 412 (25.5) 340 (26.6)
<12 μmol/L 1202 (74.5) 940 (73.4)
PT
≥12 sec 749 (46.4) 655 (51.2)
<12 sec 865 (53.6) 625 (48.8)
APTT
≥37 sec 22 (1.4) 18 (1.4)
<37 sec 1592 (98.6) 1262 (98.6)
PLT
≤100 × 103/μL 233 (14.4) 202 (15.8)
100–300 × 103/μL 1303 (80.7) 1021 (79.8)
≥300 × 103/μL 78 (4.8) 57 (4.5)
WBC
≥4 × 103/μL 1380 (85.5) 1068 (83.4)
<4 × 103/μL 234 (14.5) 212 (16.6)
HBsAg, hepatitis B surface antigen; AFP, α- fetoprotein; CA19- 9, carbo-
hydrate antigen 19- 9; CEA, carcinoembryonic antigen; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; GGT, γ- 
glutamyltransferase; ALP, alkaline phosphatase; ADA, adenosine deami-
nase; TP, total protein; ALB, albumin; PA, prealbumin; TBIL, total 
bilirubin; DBIL, direct bilirubin; TBA, total bile acid; PT, prothrombin 
time; APTT, activated partial thromboplastin time; PLT, platelet; WBC, 
white blood cell.
Table 1. (Continued)
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and microRNAs patterns including miR- 21, miR- 31 and 
miR- 122 et al. in patients with ICC or HCC have been 
explored [32]. During the past decades, the underlying 
metabolism reprogramming of cancer also led to ICC/
HCC analysis. Comprehensive analysis and comparison 
of the transcriptomes and metabolomes of ICC and HCC 
have been reported, and distinct underlying carcinogenic 
mechanisms were studied, providing specific profile of 
genes and compounds, which might be useful in diag-
nosing ICC [33]. Distinct fatty acid synthase in ICC 
and HCC specimens was decoded, and these findings 
supported some novel intervention approaches involving 
metabolism regulation [22]. Additionally, histologic labels 
were investigated and some of them were potentially 
helpful in differential diagnosis of ICC and HCC. 
Immunohistochemical analyses revealed a significant 
higher expression level of sonic hedgehog (SHH) protein 
in ICC than in HCC [5]. Li et al. [34] found that the 
CD79α (HM47/A9) antibody was effective in distinguish-
ing between ICC and HCC. Other studies also demon-
strated that anterior gradient 3 (AGR 3) and hepatocyte 
paraffin 1 were promising markers for discriminating 
ICC [17, 35]. However, all these molecules were detected 
in tissue specimens with subpar diagnostic power, still 
limiting the feasibility of their use in clinical applica-
tions. These findings may help decipher the underlying 
molecular pathways and regulation mechanisms, but there 
is still a long way from basic research to clinical trials 
and practices [36]. Imaging examination is also another 
important means for discrimination. However, the imag-
ing characteristics of ICC might overlap with those of 
HCC in dynamic enhancement patterns in contrast- 
enhanced ultrasound (CEUS) [19, 37]. Recently, MRI- 
based approaches have been developed to facilitate in 
accurate discrimination of ICC from HCC [23, 38]. 
Nevertheless, costly high- resolution equipment and expe-
rienced radiologists are not available in some developing 
areas, and many high- risk patients are still ineligible for 
MRI use.
Nomograms can provide accurate risk evaluation and 
good discrimination characteristics that can facilitate 
the evidence- based, individualized decision- making [39, 
Figure 1. Overall survival (A) and Recurrence- free survival (B) of ICC and HCC. Overall survival (C) and Recurrence- free survival (D) of high- risk group 
and low- risk group. All the P values are <0.001. ICC, intrahepatic cholangiocarcinoma; HCC, hepatocellular carcinoma.
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40]. We propose a nomogram model incorporating six 
comprehensive and easily obtainable preoperative vari-
ables (Gender, HBsAg, AST, AFP, CEA and CA19- 9) 
to discriminate ICC from HCC. It performed well in 
differentiating ICC from HCC, which were validated 
by the C- index value of 0.86 and 0.88 in the training 
and validation cohorts, respectively. The optimal cali-
bration curves demonstrated the coincidence between 
prediction and actual status. Among those factors, 
HBsAg, AST, AFP were negatively related to ICC, and 
female gender, CEA and CA19- 9 were positive param-
eters in this ICC- differential model. High levels of AST 
and AFP were more common in HCC than in ICC, 
and HBV infection is one of the major causes of HCC 
[20]. The nomogram model we have proposed can 
serve as an aid for clinical decision- making and recruit-
ing cases for randomized clinical trials including studies 
on neoadjuvant treatment for ICC. Figure 1A and B 
demonstrated poorer prognosis of ICC in our cohort 
compared with HCC, which was consistent with the 
literature and confirmed the necessity of an accurate 
discriminatory model.
To our knowledge, no nomogram model exists for dif-
ferential diagnosis of ICC and HCC. In the present study, 
we have constructed and validated a simple and intelligible 
nomogram model based on a large- scale study, which 
presented high accuracy (AUC >0.85) in a clinical setting. 
Our follow- up assessments further demonstrated the nomo-
gram’s discrimination of high- risk individuals correlated 
with poorer prognosis when compared with low- risk indi-
viduals, independent of cancer subtype (Fig. 1C and D). 
However, some limitations of this study should be acknowl-
edged. First of all, the data used in this study were obtained 
from a single institution, and multicenter validation is 
still necessary. Second, a prospective study is urgently 
needed to confirm the reliability of this model. Third, 
prognosis assessment value of this nomogram was observed 
in our small- scale follow- up study, and sample size should 
be enlarged for further validation.
Table 2. Univariate logistic regression analysis of ICC presence based on 
preoperative data in training Cohort (n = 1614).
Variables Odds ratio (95% CI) P value
Gender (Male vs. Female) 0.351 (0.267–0.462) <0.01
Age (per year) 0.972 (0.953–0.991) 0.005
AFP (20–400 vs. <20, ng/L) 0.301 (0.221–0.408) <0.01
 (>400 vs. <20, ng/L) 0.285 (0.227–0.357) <0.01
CA19- 9 (≥39 vs. <39, U/mL) 5.586 (4.369–7.141) <0.01
CEA (≥10 vs. <10, mg/mL) 25.539 
(11.563–47.918)
<0.01
Tumor Size (≥3 vs. <3, cm) 0.652 (0.578–0.735) <0.01
Tumor Capsule (Incomplete 
vs. Complete)
12.477 (9.301–16.737) <0.01
HBsAg (Positive vs. 
Negative)
0.099 (0.075–0.131) <0.01
TBIL (≥20.52 vs. <20.52, 
μmol/L)
0.897 (0.647–1.244) 0.515
DBIL (≥6.84 vs. <6.84, 
μmol/L)
0.998 (0.765–1.303) 0.991
TBA (≥12 vs. <12, μmol/L) 1.321 (1.009–1.729) 0.043
TP (≥65 vs. <65, g/L) 0.414 (0.288–0.594) <0.01
ALB (≥40 vs. <40, g/L) 0.725 (0.562–0.936) 0.014
PA (≥170 vs. <170, mg/L) 0.752 (0.581–0.972) 0.03
ALT (≥45 vs. <45, U/L) 0.821 (0.640–1.053) 0.121
AST (≥40 vs. <40, U/L) 0.738 (0.574–0.949) 0.018
GGT (≥60 vs. <60, U/L) 1.461 (1.161–1.839) 0.001
ALP (≥125 vs. <125, U/L) 3.360 (2.593–4.353) <0.01
ADA (≥7 vs. <7, U/L) 1.482 (1.178–1.866) 0.001
PT (≥12 vs. <12, sec) 0.604 (0.479–0.762) <0.01
APTT (≥37 vs. <37, sec) 0.888 (0.326–2.423) 0.817
ICC, intrahepatic cholangiocarcinoma; AFP, α- fetoprotein; CA19- 9, carbo-
hydrate antigen 19- 9; CEA, carcinoembryonic antigen; HBsAg, hepatitis B 
surface antigen; TBIL, total bilirubin; DBIL, direct bilirubin; TBA, total bile 
acid; TP, total protein; ALB, albumin; PA, prealbumin; ALT, alanine ami-
notransferase; AST, aspartate aminotransferase; GGT, γ- glutamyltransferase; 
ALP, alkaline phosphatase; ADA, adenosine deaminase; PT, prothrombin 
time; APTT, activated partial thromboplastin time.
Table 3. Multivariate logistic regression analysis of ICC presence based 
on preoperative data in the training cohort (n = 1614).
Variables β Odds ratio (95% CI) P value
Gender (Male vs. 
Female)
0.831 2.295 (1.554–3.389) <0.01
HBsAg (Positive vs. 
Negative)
−1.825 0.161 (0.111–0.234) <0.01
TBA (≥12 vs. <12, 
μmol/L)
−0.431 0.650 (0.444–0.952) 0.027
TP (≥65 vs. <65, 
g/L)
−0.644 0.525 (0.328–0.841) 0.007
AST (≥40 vs. <40, 
U/L)
−0.863 0.422 (0.287–0.620) <0.01
ALP (≥125 vs. 
<125, U/L)
0.425 1.530 (1.023–2.289) 0.039
ADA (≥7 vs. <7, 
U/L)
0.728 2.071 (1.473–2.912) <0.01
AFP (20–400 vs. 
<20, ng/L)
−0.990 0.372 (0.261–0.529) <0.01
(>400 vs. <20, 
ng/L)
−2.312 0.099 (0.060–0.163) <0.01
CEA (≥10 vs. <10, 
mg/mL)
1.808 6.100 (2.472–15.053) <0.01
CA19- 9 (≥39 vs. 
<39, U/mL)
1.842 6.306 (4.440–8.956) <0.01
PT (≥12 vs. <12, 
sec)
−0.336 0.714 (0.517–0.987) 0.042
ICC, intrahepatic cholangiocarcinoma; HBsAg, hepatitis B surface anti-
gen; TBA, total bile acid; TP, total protein; AST, aspartate aminotrans-
ferase; ALP, alkaline phosphatase; ADA, adenosine deaminase; AFP, 
α- fetoprotein; CEA, carcinoembryonic antigen; CA19- 9, carbohydrate 
antigen 19- 9; PT, prothrombin time.
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Conclusions
By combining six commonly assessed preoperative fac-
tors, a differential diagnostic model was established 
using nomogram analysis for optimal discrimination of 
ICC from HCC in a large- scale, single- center study 
and validated for accuracy. Further independent mul-
ticenter investigation is necessary to expand the 
Figure 2. (A) Nomogram to discriminate ICC from HCC. To use the nomogram, match patient results for each parameter to a position on their 
corresponding axis, then draw a line to the Points axis at the top of the Nomogram to calculate the respective points for each parameter; finally, 
add the total points from all parameters, and draw a line from the Total Points axis to the Risk Probability axis at the bottom of the nomogram 
to determine ICC presence probabilities. (B) Validity of the discrimination efficacy in the training cohort (n = 1614). (C) Validity of the 
discrimination efficacy in the validation cohort (n = 1280). HBsAg, hepatitis B surface antigen; AST, aspartate aminotransferase; AFP, alpha- 
fetoprotein; CEA, carcinoembryonic antigen; CA19- 9, carbohydrate antigen 19- 9; C, concordance index; ROC, receiver operating characteristic.
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validation for precision therapy and prognosis 
improvement.
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